Praluent and Pregabalin Interaction: What Patients and Clinicians Need to Know

Why This Interaction Question Arises

Patients with established atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia frequently carry a heavy medication burden. Adding pregabalin for neuropathic pain, fibromyalgia, or seizure control to an existing Praluent regimen is common enough that clinicians and pharmacists field this question regularly.

The short answer: no clinically meaningful pharmacokinetic interaction has been documented between alirocumab and pregabalin. The longer answer requires understanding why that is, and what pharmacodynamic risks still deserve attention.

Who Is Taking Both Drugs?

Patients with type 2 diabetes frequently develop both ASCVD (driving alirocumab use) and diabetic peripheral neuropathy (driving pregabalin use). A 2021 analysis in JAMA Cardiology noted that polypharmacy in ASCVD patients averages 8.2 concurrent medications, creating compounded interaction questions even when no direct biochemical pathway exists [1].

Patients with familial hypercholesterolemia may also develop chronic pain syndromes unrelated to their lipid disorder, landing them on pregabalin. Understanding the mechanistic basis for a lack of interaction is as clinically useful as documenting one.

Alirocumab: Mechanism, Metabolism, and Pharmacokinetics

Alirocumab is a fully human IgG1 monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, it prevents the degradation of hepatic LDL receptors, increasing receptor recycling and reducing circulating LDL-C [2].

Metabolic Pathway

Monoclonal antibodies are not substrates for cytochrome P450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4) or for drug transporters such as P-glycoprotein (P-gp), OATP1B1, or BCRP. Alirocumab is cleared through two routes: target-mediated drug disposition (binding to PCSK9 and subsequent internalization) and nonspecific proteolytic catabolism into constituent amino acids [3].

This route of elimination means that inhibitors or inducers of hepatic enzymes have no effect on alirocumab exposure. Ketoconazole, rifampin, statins, and pregabalin alike do not alter alirocumab plasma concentrations.

Key Pharmacokinetic Parameters

The FDA-approved Praluent prescribing information reports a mean half-life of 17 to 20 days after subcutaneous injection, with peak plasma concentration reached in 3 to 7 days [3]. Bioavailability after SC injection is approximately 85%. No renal or hepatic dose adjustment is required because the molecule does not depend on those organs for clearance.

Clinical Efficacy Context

In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75 to 150 mg SC every 2 weeks reduced major adverse cardiovascular events (MACE) by 15% compared with placebo (hazard ratio 0.85; 95% CI 0.78 to 0.93; P<0.001) in patients with recent acute coronary syndrome on maximally tolerated statin therapy [4]. LDL-C reductions from baseline averaged 54.7% at 12 months. That level of LDL-C reduction is not attenuated by concurrent pregabalin use.

Pregabalin: Mechanism, Metabolism, and Pharmacokinetics

Pregabalin (Lyrica) binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central and peripheral nervous system. This binding reduces calcium influx at nerve terminals, decreasing the release of excitatory neurotransmitters including glutamate and substance P [5].

Metabolic Pathway

Pregabalin undergoes negligible hepatic metabolism. Approximately 90% of an absorbed dose is recovered in the urine as unchanged drug [5]. The small metabolized fraction produces N-methylpregabalin, which is pharmacologically inactive. There is no significant CYP involvement. Renal clearance of pregabalin correlates directly with creatinine clearance, making renal function the dominant pharmacokinetic variable.

Renal Dose Adjustments for Pregabalin

Because pregabalin clearance tracks renal function, dose reductions are required when creatinine clearance falls below 60 mL/min:

• CrCl 30 to 60 mL/min: 150 to 300 mg/day
• CrCl 15 to 30 mL/min: 75 to 150 mg/day
• CrCl <15 mL/min: 25 to 75 mg/day
• Patients on hemodialysis require supplemental doses after each session [5]

Patients with ASCVD often have concurrent chronic kidney disease (CKD). Any patient receiving both alirocumab and pregabalin should have creatinine clearance checked at least annually to guide pregabalin dosing.

Sedation and CNS Depression

Pregabalin produces dose-dependent dizziness, somnolence, and cognitive slowing. The FDA label for Lyrica notes that somnolence was reported in 21 to 28% of patients in clinical trials at doses of 300 to 600 mg/day, compared with 8% on placebo [5]. That risk compounds when pregabalin is combined with other CNS depressants, including opioids, benzodiazepines, or alcohol.

Pharmacokinetic Interaction Assessment: Alirocumab Plus Pregabalin

The interaction potential between these two drugs is low for straightforward mechanistic reasons.

No Shared Enzymatic Pathway

Alirocumab bypasses the entire hepatic CYP enzyme system. Pregabalin similarly bypasses it. There is no competition for CYP binding sites, no inhibition of shared transporters, and no protein-binding displacement (alirocumab is a large-molecular-weight antibody with distinct binding characteristics; pregabalin is a small molecule with low protein binding of approximately 0%) [5].

No Transporter Competition

OATP1B1, OATP1B3, OAT1, OAT3, and P-gp are the most clinically consequential drug transport proteins. Pregabalin is a substrate of large neutral amino acid transporters (LAT1, LAT2) for intestinal absorption, not of the hepatic or renal transporters that govern small-molecule drug-drug interactions. Alirocumab does not interact with amino acid transporters. Overlap is zero.

Protein Binding

Pregabalin's protein binding is essentially zero. Displacement interactions require high protein binding (generally above 85 to 90%). Alirocumab, as a monoclonal antibody, binds specifically to PCSK9 rather than to serum albumin or alpha-1 acid glycoprotein. No displacement dynamic is possible.

HealthRX Three-Gate Interaction Framework for Biologic-Small Molecule Pairs

When a PCSK9 inhibitor (or any therapeutic monoclonal antibody) is combined with a small molecule, clinicians can apply a three-gate check:

1. Gate 1: CYP involvement. Is either drug a CYP substrate, inhibitor, or inducer? If neither drug involves CYP enzymes, pharmacokinetic interaction is highly unlikely.
2. Gate 2: Transporter overlap. Do both drugs use the same hepatic or renal transport proteins (P-gp, BCRP, OATP1B1)? If not, elimination interference is unlikely.
3. Gate 3: Pharmacodynamic convergence. Do both drugs produce overlapping physiological effects (CNS depression, QT prolongation, bleeding, electrolyte shifts)? If yes, additive or synergistic effects require monitoring even without a pharmacokinetic mechanism.

For alirocumab plus pregabalin: Gate 1 passes (no CYP for either), Gate 2 passes (no transporter overlap), Gate 3 requires attention only in patients on multiple CNS-active drugs alongside pregabalin.

Pharmacodynamic Considerations: Where Clinical Vigilance Still Matters

No pharmacokinetic interaction does not mean zero clinical concern. Pharmacodynamic interactions can arise when drugs independently produce similar physiological effects that add together.

CNS Depression Burden in ASCVD Patients

Patients on alirocumab for ASCVD are often co-prescribed medications that carry their own CNS load: beta-blockers (fatigue), high-dose statins (occasional myopathy-related pain leading to opioid use), antihypertensives (dizziness), and sometimes anti-anxiety agents. Adding pregabalin, which by itself causes somnolence in roughly a quarter of patients at therapeutic doses, increases the cumulative CNS depression burden.

Alirocumab itself does not produce CNS depression. Its adverse event profile in ODYSSEY OUTCOMES was dominated by injection-site reactions (7.2% vs. 5.1% placebo) and a small signal for neurocognitive events that has not been confirmed in subsequent analysis [4].

Falls and Fracture Risk

The American Geriatrics Society 2023 Beers Criteria list pregabalin as a medication with high fall and fracture risk, particularly in adults over age 65 [6]. Many patients on alirocumab for secondary prevention are in that age bracket. A clinician co-prescribing pregabalin to an older ASCVD patient should assess baseline fall risk, consider the lowest effective pregabalin dose, and review all other CNS-active medications before adding pregabalin.

Cardiovascular Neutrality of Pregabalin

The FORTE trial (N=1,565) evaluated pregabalin in patients with post-surgical neuropathic pain and found no adverse cardiovascular signal versus placebo [7]. Pregabalin does not prolong the QT interval, does not increase blood pressure, and does not interfere with lipid physiology. From a cardiovascular pharmacodynamics standpoint, it is neutral alongside alirocumab.

Peripheral Edema

Pregabalin produces peripheral edema in 6 to 16% of patients at doses of 300 to 600 mg/day [5]. Patients with heart failure or reduced ejection fraction, who may be on alirocumab for secondary prevention, could find that edema complicates fluid management. This is not an alirocumab-pregabalin interaction; it is a pregabalin adverse effect that clinicians should weigh against the patient's cardiac status.

What the FDA Labels Say

The Praluent (alirocumab) prescribing information, last revised in 2023, contains no drug interaction section listing pregabalin or any other specific concomitant medication beyond a general statement that, as a biologic, alirocumab is not expected to participate in CYP-mediated interactions [3].

The Lyrica (pregabalin) prescribing information lists interactions with opioid analgesics (additive CNS and respiratory depression), lorazepam (additive cognitive impairment), ethanol, and thiazolidinediones (fluid retention). Alirocumab does not appear in the pregabalin interaction table [5].

Neither label requires dose adjustment when both drugs are co-administered.

DDI Database Classification

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) classify the alirocumab-pregabalin combination as having no established interaction or "no interaction found." This aligns with the mechanistic analysis above.

The Micromedex severity scale runs from Contraindicated to Major to Moderate to Minor to No Interaction. Alirocumab plus pregabalin falls in the No Interaction category within that classification system.

Clinicians should note that database entries are not infallible. A mechanistically implausible interaction listed as "no data" in a database should not be confused with a confirmed safety finding. In this case, mechanism and database classification agree.

Monitoring Recommendations When Co-Prescribing

Even without a pharmacokinetic interaction, structured monitoring protects patients receiving both drugs.

LDL-C Monitoring for Alirocumab

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction recommends checking fasting lipid panels 4 to 12 weeks after starting or adjusting a PCSK9 inhibitor, then every 3 to 12 months thereafter [8]. A subtherapeutic LDL-C response to alirocumab should prompt evaluation of injection technique, adherence, and whether a dose escalation from 75 mg to 150 mg every 2 weeks is appropriate.

Renal Function for Pregabalin Clearance

Check serum creatinine and calculate CrCl at pregabalin initiation and then annually, or more frequently in patients with progressive CKD. Since patients with ASCVD have elevated CKD risk, this is a meaningful safety step, entirely independent of alirocumab.

CNS Adverse Effect Monitoring

At each follow-up visit, ask directly about dizziness, somnolence, concentration difficulties, and falls. The PHQ-9 or a brief fall-risk screen (Timed Up and Go test, taking longer than 12 seconds signals elevated risk) can be incorporated into quarterly telehealth check-ins [9].

Pregabalin Schedule V Status

Pregabalin carries Schedule V controlled substance status in the United States due to documented abuse and misuse potential. A 2019 pharmacovigilance review in the British Medical Journal identified 8,831 pregabalin-related deaths in England between 2004 and 2019, most involving polysubstance use [10]. Clinicians prescribing pregabalin alongside any other regimen should maintain prescription drug monitoring program (PDMP) checks and assess for aberrant drug-related behaviors at each visit.

Patient Counseling Points

Patients asking "can I take Praluent with pregabalin?" deserve a clear, jargon-free answer, plus practical safety guidance.

What to Tell Patients

• Praluent is given as an injection under the skin every 2 or 4 weeks. It works entirely differently from oral medications and does not go through the liver's drug-processing enzymes. Pregabalin also avoids those enzymes. So the two drugs do not interfere with each other's blood levels.
• Pregabalin can cause dizziness and drowsiness, especially in the first few weeks or after a dose increase. If you feel unsteady, sit before standing, and avoid driving until you know how the medication affects you.
• Tell every prescriber and pharmacist about both medications so they can check for interactions with any new drug added to your regimen.
• Do not stop either medication without talking to your care team. Stopping alirocumab abruptly will cause LDL-C to rebound within weeks. Stopping pregabalin abruptly can cause withdrawal symptoms including headache, insomnia, and in rare cases, seizures.
• If you notice swollen ankles or legs after starting pregabalin, report this promptly, especially if you have heart failure.

Injection-Site Guidance for Alirocumab

Alirocumab should be injected at room temperature (removed from refrigerator 30 to 40 minutes before use). Rotate injection sites among the abdomen, thigh, and upper arm. Do not inject into skin that is bruised, tender, or scarred. These instructions are unchanged by concurrent pregabalin use.

Special Populations

Older Adults (Age 65 and Above)

Alirocumab's cardiovascular benefit persists in older adults. A pre-specified subgroup analysis of ODYSSEY OUTCOMES found consistent MACE reduction across age groups, with no signal of harm in patients above 65 [4]. Pregabalin, however, requires more caution in older adults due to fall risk and the potential for cognitive adverse effects. The lowest effective dose should be used, and CNS-active polypharmacy should be reviewed before adding pregabalin to an older patient's regimen.

Patients With Chronic Kidney Disease

Alirocumab requires no renal dose adjustment. Pregabalin requires significant dose reduction as CrCl falls below 60 mL/min. ASCVD patients with CKD stage 3 or worse should have pregabalin doses calculated explicitly from measured or estimated CrCl before the first prescription is written.

Patients With Diabetes

Diabetic patients on alirocumab for ASCVD and pregabalin for peripheral neuropathy represent the most common overlap population. The ODYSSEY DM-DYSLIPIDEMIA trial (N=413) demonstrated that alirocumab 75 mg every 2 weeks reduced non-HDL-C by 43.0% versus usual care in patients with type 2 diabetes and mixed dyslipidemia [11]. Pregabalin efficacy in diabetic peripheral neuropathy was established in a key 12-week trial (N=338) showing 4.9-point mean reduction in daily pain score on an 11-point scale versus 2.1 points with placebo [12]. These drugs address distinct complications of diabetes and may both be necessary simultaneously.

Summary Table: Alirocumab vs. Pregabalin Pharmacokinetic Profile

| Parameter | Alirocumab (Praluent) | Pregabalin (Lyrica) | |---|---|---| | Drug class | PCSK9 inhibitor (mAb) | Alpha-2-delta calcium channel ligand | | CYP metabolism | None | Negligible (<2%) | | Primary elimination | Proteolytic catabolism; TMDD | Renal excretion (unchanged, ~90%) | | Protein binding | Binds PCSK9 specifically | ~0% | | P-gp substrate | No | No | | Half-life | 17 to 20 days | 6.3 hours | | Renal dose adjustment | Not required | Required if CrCl <60 mL/min | | Hepatic dose adjustment | Not required | Not required | | CNS effects | None reported | Somnolence, dizziness (21 to 28%) | | Interaction with each other | None established | None established |

When to Consult a Clinical Pharmacist or Specialist

Co-prescribing alirocumab and pregabalin rarely requires specialist consultation based on the interaction profile alone. Consultation is appropriate in three specific scenarios:

First, when the patient has CrCl <30 mL/min: pregabalin dosing becomes complex and the risk of accumulation-related toxicity rises. A clinical pharmacist can calculate adjusted dosing based on current renal function and dialysis schedule.

Second, when the patient is on three or more CNS-active medications concurrently (for example, opioids plus a benzodiazepine plus pregabalin): the cumulative sedation burden warrants a formal medication review. The CDC's 2022 Clinical Practice Guideline for Prescribing Opioids specifically flags concurrent gabapentinoids and opioids as a combination requiring close monitoring for respiratory depression [9].

Third, when the patient is being evaluated for familial hypercholesterolemia and has comorbid epilepsy requiring high-dose pregabalin: a multidisciplinary review ensures that both conditions are optimally treated without overlooking rare pharmacodynamic effects from the full medication panel.